Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.
Today, on 3 July 2025, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) rights issue of shares of series A with preferential rights for existing shareholders up to approximately MSEK 136 (the “Rights Issue”), which was resolved and announced on 24 June 2025. The subscription period for the Rights Issue will run until and including 17 July 2025. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.
Summary of the Rights Issue
- The Rights Issue comprises a maximum of 38,901,304 shares of series A.
- Upon full subscription, IRLAB will receive approximately MSEK 136 before deduction of issue-related costs.
- The subscription price is SEK 3.50 per share.
- The Rights Issue is covered by subscription undertakings amounting to approximately 33 percent, corresponding to approximately MSEK 44. The Company has furthermore entered into agreements on guarantee undertakings which amounts to a total of approximately MSEK 71, corresponding to approximately 52 percent of the Rights Issue.
- In total, approximately 85 percent of the Rights Issue is thus secured by subscription and guarantee undertakings.
- Anyone who was registered in the share register as a shareholder in IRLAB on the record date of 1 July 2025 received one (1) subscription right for each (1) share held, regardless of share series.
- Four (4) subscription rights entitle for subscription of three (3) newly issued shares of series A.
- Shareholders who choose not to participate in the Rights Issue will have their ownership diluted by up to approximately 42.9 percent but will have the opportunity to compensate themselves financially for the dilution effect by selling their subscription rights.
- Full terms and conditions for the Rights Issue and other information about the Company are set out in the appendix IX information document published by the Company on 2 July 2025.
The information document and other information about the Rights Issue is available on the Company’s and Eminova Fondkommission AB’s respective websites, www.irlab.se and www.eminova.se.
Indicative time plan
The following time plan for the Rights Issue is preliminary and subject to change.
Trading in subscription rights | 3 July 2025 – 14 July 2025 |
Subscription period | 3 July 2025 – 17 July 2025 |
Trading in paid subscribed shares (BTA) | 3 July 2025 – week 31, 2025 |
Expected day for announcement of the outcome | 21 July 2025 |
Advisers
MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue.